GlassScriptPhysician profile
Lindsey Powell
NPI 1215688452
$7,877.39
in general payments reported to CMS, 2019-2025
29 companies · $223 in 2025
The $223 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,470 · 2023: $2,442 · 2024: $2,742 · 2025: $223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,220 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,220.12 |
| Education | $187.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,454.29 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,410.57 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,383.70 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $727.16 | 2022-2024 | Hyqvia, Takhzyro, Cuvitru |
| Amgen INC. | $357.65 | 2022-2024 | Tezspire |
| Csl Behring | $334.04 | 2023-2025 | Haegarda, Hizentra |
| Pfizer INC. | $319.89 | 2022-2024 | |
| Biocryst US Sales Co., LLC | $295.07 | 2022-2024 | Orladeyo |
| Leo Pharma INC. | $196.87 | 2022-2023 | Adbry |
| Kaleo, INC. | $156.19 | 2022-2024 | Auvi-Q |
| Beta Bionics, INC. | $154.72 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Teva Pharmaceuticals USA, INC. | $148.52 | 2022 | |
| Grifols USA, LLC | $137.93 | 2022-2024 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $116.06 | 2023-2024 | |
| Genentech USA, INC. | $101.23 | 2022-2024 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $93.49 | 2024 | |
| Aytu Biopharma, INC. | $87.00 | 2022-2024 | Karbinal |
| Optinose US, INC. | $71.09 | 2022-2024 | |
| Hikma Pharmaceuticals USA | $53.92 | 2023-2024 | Ryaltris |
| Octapharma USA, INC. | $48.78 | 2022-2024 | Panzyga |
| Alk-Abello, INC | $38.76 | 2022-2023 | Grastek, Ragwitek, Odactra |
| Covis Pharma Gmbh | $33.27 | 2022 | |
| Incyte Corporation | $32.18 | 2023-2024 | Opzelura |
| Insmed, INC. | $26.68 | 2024 | Arikayce |
| Ars Pharmaceuticals Operations, INC. | $24.32 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.10 | 2024 | Spiriva Respimat |
| Phadia US INC. | $17.76 | 2022 | |
| Pharming Healthcare, INC. | $16.32 | 2022 | |
| Cequr Corporation | $15.83 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.